Artal Group’s Fate Therapeutics FATE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2024
Q3
Sell
-1,032,500
Closed -$3.39M 34
2024
Q2
$3.39M Buy
1,032,500
+672,189
+187% +$2.2M 0.09% 64
2024
Q1
$2.64M Buy
+360,311
New +$2.64M 0.07% 76
2023
Q2
Sell
-2,600,000
Closed -$14.8M 121
2023
Q1
$14.8M Hold
2,600,000
0.88% 29
2022
Q4
$26.2M Hold
2,600,000
1.46% 22
2022
Q3
$58.3M Hold
2,600,000
2.49% 9
2022
Q2
$64.4M Buy
2,600,000
+600,000
+30% +$14.9M 3.44% 9
2022
Q1
$77.5M Buy
2,000,000
+200,000
+11% +$7.75M 3.25% 8
2021
Q4
$105M Buy
1,800,000
+350,000
+24% +$20.5M 2.86% 8
2021
Q3
$85.9M Buy
1,450,000
+100,000
+7% +$5.93M 1.92% 11
2021
Q2
$117M Buy
1,350,000
+50,000
+4% +$4.34M 2.38% 9
2021
Q1
$107M Sell
1,300,000
-100,000
-7% -$8.25M 1.89% 10
2020
Q4
$127M Sell
1,400,000
-100,000
-7% -$9.09M 2.73% 6
2020
Q3
$60M Sell
1,500,000
-300,000
-17% -$12M 1.46% 13
2020
Q2
$61.8M Sell
1,800,000
-300,000
-14% -$10.3M 1.73% 12
2020
Q1
$46.6M Buy
2,100,000
+100,000
+5% +$2.22M 1.97% 12
2019
Q4
$39.1M Hold
2,000,000
1.51% 12
2019
Q3
$31.1M Buy
2,000,000
+500,000
+33% +$7.77M 1.25% 13
2019
Q2
$30.5M Sell
1,500,000
-300,000
-17% -$6.09M 1.23% 17
2019
Q1
$31.6M Sell
1,800,000
-350,000
-16% -$6.15M 1.29% 16
2018
Q4
$27.6M Sell
2,150,000
-40,000
-2% -$513K 1.02% 15
2018
Q3
$35.7M Buy
2,190,000
+490,000
+29% +$7.98M 0.93% 12
2018
Q2
$19.3M Buy
1,700,000
+850,000
+100% +$9.64M 0.41% 16
2018
Q1
$8.3M Buy
+850,000
New +$8.3M 0.1% 31